High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma

European Journal of Surgical Oncology

Volumn 32, Issue 10, 2006, Pages 1097-1100

  Biron Shental, T ^a   Drucker, L ^a   Altaras, M ^a   Bernheim, J ^a   Fishman, A ^a  

^a MEIR MEDICAL CENTER   (Israel)

Author keywords

BRCA1 2 mutations; Uterine serous papillary carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; GENOMIC DNA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; FAMILIAL CANCER; FOUNDER EFFECT; GENE AMPLIFICATION; GENE DELETION; GENE INSERTION; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; JEW; OVARY CANCER; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERUS CARCINOMA;

AGED; BREAST NEOPLASMS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; JEWS; MIDDLE AGED; POLYMERASE CHAIN REACTION; UTERINE NEOPLASMS;

EID: 33751179216     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.032     Document Type: Article

References (22)

1. Hendrickson M., Martinez A., Ross J., Kempson R., and Eifel P. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6 (1982) 93-108
2. Rosenberg P., Blom R., Hogberg T., and Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 51 (1993) 311-315
3. Gallion H.H., Nagell J.R., Powell D.F., Donaldson E.S., Higgins R.V., Kryscio R.J., et al. Stage I serous papillary carcinoma of the endometrium. Cancer 63 (1989) 2224-2228
4. Ward B.G., Wright R.G., and Free K. Papillary carcinomas of the endometrium. Gynecol Oncol 39 (1990) 347-351
5. Piura B., Meirovitz M., Shulman M., Yanai-Inbar I., and Cohen Y. Uterine papillary serous carcinoma: study of 19 cases. Eur J Obstet Gynecol Reprod Biol 79 (1998) 69-73
6. Kato D.T., Ferry J.A., Goodman A., Sullinger J., Scully R.E., Goff B.A., et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol 59 (1995) 384-389
7. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Eng J Med 336 (1997) 1401-1408
8. Modan B., Gak E., Sade-Bruchim R.B., Hirsh-Yechezkel G., Theodor L., Lubin F., et al. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA 276 (1996) 1823-1825
9. Levy-Lahad E., Catane R., Eisenberg S., Kaufman B., Hornreich G., Lishinsky E., et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel. Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60 (1997) 1059-1067
10. Hornreich G., Beller U., Lavie O., Renbaum P., Cohen Y., and Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 75 (1999) 300-304
11. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol Oncol 79 (2000) 477-481
12. Lavie O., Hornreich G., Ben Arie A., Renbaum P., Levy Lahad E., and Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 96 (2000) 28-32
13. Lavie O., Hornreich G., Ben-Arie A., Rennert G., Cohen Y., Keidar R., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92 (2004) 521-524
14. Geisler J.P., Sorosky J.I., Duong H.L., Buekers T.E., Geisler M.J., Sood A.K., et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol 83 (2001) 501-503
15. Rohlfs E.M., Learning W.G., Friedman K.J., Couch F.J., Weber B.L., and Silverman L.M. Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43 (1997) 24-29
16. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60 (1997) 505-514
17. Roa B.B., Boyd A.A., Volcik K., and Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14 (1996) 185-187
18. Boyd J. Specific keynote: hereditary ovarian cancer: what we know?. Gynecol Oncol 88 (2003) 8-10
19. Levine D.A., Lin O., Baraket R.R., Robson M.E., McDermott D., Cohen L., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 80 (2001) 395-398
20. Goldman N.A., Goldberg G.L., Runowicz C.D., Anderson P.S., and Fields A.L. BRCA mutations in women with concurrent breast cancer and uterine papillary serous carcinoma. ASCO Proc 21 (2002) 221a
21. Caduff R.F., Sovoboda-Newman S.M., Bartons R.E., Ferguson A.W., and Frank T.S. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol 22 (1998) 319-326
22. Karlan B.Y. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol 92 (2004) 519-520